YD Biolabs, founded by Dr. Cheng-Yao Chen, is advancing the field of synthetic biology by deploying its proprietary enzymatic DNA synthesis (Next-Generation DNA Synthesis, NGDS) platform directly into research and clinical laboratories. Dr. Chen, with experience at Illumina, emphasizes that while DNA sequencing costs have plummeted nearly a million-fold, DNA synthesis costs have only modestly declined—highlighting the critical need for innovation in synthesis technology.
This NGDS platform aims to bridge the growing cost gap between sequencing and synthesis and democratize DNA writing capabilities. Dr. Chen envisions a future where integrated read-and-write DNA systems are common in labs, positioning DNA not only as a tool for biology, but as a medium for data storage and interface between digital and physical worlds.
YD Biolabs is proud to be featured in GBI Monthly, highlighting our proprietary Next-Generation DNA Synthesis (NGDS) technology. The article showcases how our enzymatic DNA synthesis platform is making its way into research and clinical laboratories, addressing the cost gap between DNA sequencing and synthesis.
